Summit Biosciences Inc.

Crescent Biopharma may be behind in the race to introduce a PD-1xVEGF bispecific antibody, but the firm has a clearer path now that it is going public through a reverse merger with GlycoMimetics and

After abuse-deterrent opioid formulations reached a dead-end, the US Food and Drug Administration again is seeing growth in applications for new products that address the opioid crisis. In addition to

After abuse-deterrent opioid formulations reached a dead-end, the US FDA is again seeing growth in applications for new products that address the opioid crisis, led by not one but two applications for